Healthcare
April 15, 2025
Filipa Ćavar, Josipa Mihić, Goran Milas
3 citations
Background/Objectives: Adolescence is a critical period for mental health, with depression increasing rapidly and often leading to lifelong consequences. In recent decades, the prevalence of elevated depressive symptoms among adolescents has steadily risen, making it a significant public health concern. While research supports the benefits of mindfulness-based practices in reducing adolescent...
Psychedelic Medicine
April 14, 2025
Caroline Hayes
As the therapeutic potential of psychedelics is becoming more established, a wider range of compounds are beginning to be investigated for their antidepressant properties. 5-Methoxy- N , N -dimethyltryptamine (5-MeO-DMT) is one such example; its unusual properties may make it a more cost-effective and practical choice for health care providers. However, the same distinctive features may mean...
International Journal of Molecular Sciences
April 10, 2025
Mădălina Iuliana Mușat, Ana-Maria Ifrim-Predoi, Smaranda Ioana Mitran et al.
5 citations
Non-alcoholic fatty liver disease (NAFLD) has been associated with depression and inadequate response to antidepressants. While ketamine has demonstrated efficacy in treating depression, its impact on pre-existing liver injury and depression remains unclear. This study aimed to evaluate the effects of ketamine treatment in a murine model of depression and liver damage, considering age-related...
Journal of Spirituality in Mental Health
April 9, 2025
Sheetal Goyal, Prasanna Krishna Bg, V.V.V. Pradeep Sastry et al.
ABSTRACT Our study investigated the effects of guided group meditation sessions on the psychological parameters of depression, stress, anxiety and anger. The present study of 212 participants followed a mixed methods approach. Data was collected using standardized psychological scales and qualitative interview pre- and post-group meditation. Findings revealed a statistically significant...
Psychopharmacology Bulletin
April 8, 2025
Keming Gao, Buket Koparal, Evrim Bayrak Oruc et al.
99 citations
In this case report, we present a patient with treatment-resistant depression (TRD) and comorbid generalized anxiety disorder, eating disorder, post-traumatic stress disorder, and borderline personality disorder. Over a 10-year period, our case transitioned from adolescence to adulthood and received antidepressant monotherapy, adjunctive therapy with antipsychotics, lithium, or lamotrigine,...
Current Neuropharmacology
April 7, 2025
Marika Alborghetti, Luana Lionetto, Ginevra Lombardozzi et al.
1 citation
Esketamine is administered intranasally in combination with at least another antidepressant in patients with treatment-resistant depression. Some of these antidepressants might affect ketamine's pharmacokinetic profile by inhibiting cytochrome-P450 (CYP450) isoforms. Our aim was to establish how different types of combined antidepressants affect serum and salivary levels of esketamine at the...
Scientific Reports
April 6, 2025
Nan Liu, Junchen Deng, Fang Lu et al.
The postpartum period has witnessed increasing rates of depression and anxiety, particularly in the context of the COVID-19 pandemic, with these conditions often co-occurring and being exacerbated by the lingering effects of long COVID. Traditional interventions, such as mindfulness-based stress reduction (MBSR) and yoga, have demonstrated effectiveness in alleviating these symptoms. However,...
Journal of Medicine and Life Sciences
April 5, 2025
Yuhang Qi, Bruce Park, Jian Madesen
Depression remains a leading cause of disability worldwide, with up to 40% of patients failing to achieve adequate response with conventional treatments. This paper introduces the Mindfulness-Acupuncture (MA) protocol, a pioneering 12-week intervention that systematically integrates acupuncture and mindfulness practices to address the multifaceted nature of depression. The theoretical framework...
Journal of Education, Health and Sport
April 5, 2025
Joanna Dmochowska, Marcin Ciechański, Joanna Cieszkowska et al.
1 citation
Introduction: Depression, affecting 350 million people globally, is a leading cause of disability. Common symptoms include low mood, sadness, guilt, anxiety, and suicidalthoughts. Current treatments, mostly monoamine-based antidepressants, have limitations such as delayed effects and low efficacy, with over 60% of patients not achieving lasting remission. Ketamine, an NMDA antagonist, has shown...
Brain, Behavior, and Immunity
April 4, 2025
Manivel Rengasamy, Benjamin Panny, Zakary Hutchinson et al.
3 citations
Ketamine is a rapid-acting treatment for treatment-resistant depression (TRD), though mechanisms related to ketamine's effects remain unclear. Blood-based neurotrophic and inflammatory factors (NIFs; e.g., brain-derived neurotrophic factor, interleukin-6) have emerged as markers potentially linked to ketamine and ketamine treatment response. In this secondary analysis of a randomized controlled...